PREDIX HER2 - preoperative treatment of HER2 positive breast cancer : PREDIX HER2 - Neoadjuvant response-guided treatment of HER2 positive breast cancer. Part of a platform of translational phase II trials based on molecular subtypes - PREDIX HER2

Medienart:

Klinische Studie

Erscheinungsjahr:

2019

Erschienen:

2019

Enthalten in:

WHO International Clinical Trials Registry Platform - (2019) vom: 16. Dez. Zur Gesamtaufnahme - year:2019

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: Primary breast cancer MedDRA version: 20.0Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.1Level: LLTClassification code 10006191Term: Breast cancer male NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.1Level: LLTClassification code 10006188Term: Breast cancer female NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]
Phase: Phase 2
Recruitment Status: Authorised-recruitment may be ongoing or finished
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 29-08-2014, Last updated: 2022-11-24

ICTRP ID:

EUCTR2014-000808-10-SE
PREDIX-HER2

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG004326512